Tamara Rordorf

University Hospital of Zurich — Switzerland

Medicine · Health Sciences

21h-index13.4kcitations60works3.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Head and Neck Cancer Studies(27), Cancer Immunotherapy and Biomarkers(22), Cancer Diagnosis and Treatment(9), Lung Cancer Treatments and Mutations(6), Brain Metastases and Treatment(6)

Publications59 total

Distant Pulmonary Metastasis in Microsecretory Adenocarcinoma of the Salivary Gland: A Case Report Highlighting Histological Variation and Aggressive Potential
International Journal of Surgical Pathology·2025Open Access
Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial
Experimental Hematology and Oncology·2025· 1 citedOpen Access
Survival outcomes after systemic treatment of high-grade triple-negative metaplastic breast cancer versus triple-negative breast cancer of no special type
Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin·2025Open Access
Biological behavior of DCIS with or without microinvasion. Same and different
Human Pathology·2025Open Access
Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study
European Journal of Cancer·2025· 19 cited
59P Long term survival data from all recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients treated with MVX-ONCO-1 during open-labelled phase I and phase IIa clinical trials
Immuno-Oncology Technology·2024Open Access
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial
European Journal of Cancer·2023· 1 citedOpen Access
106P Treatment sequencing in PD-L1–positive recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Exploratory analysis of the phase III KEYNOTE-048 study
Immuno-Oncology Technology·2023· 1 citedOpen Access
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
Journal of Clinical Oncology·2022· 442 citedOpen Access
659MO Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
Annals of Oncology·2022· 14 citedOpen Access
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Oral Oncology·2022· 36 citedOpen Access
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
The Oncologist·2022· 47 citedOpen Access
SalvGlandDx – a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets
Neoplasia·2021· 73 citedOpen Access
915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Annals of Oncology·2020· 11 cited
Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis
Cancer Research·2020· 15 cited
Consolidation cetuximab after concurrent triplet radiochemotherapy+cetuximab in patients with advanced head and neck cancer: A randomized phase II study
Radiotherapy and Oncology·2020· 4 cited
KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Journal of Clinical Oncology·2020· 24 cited
Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.
Journal of Clinical Oncology·2020· 4 cited
IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes
Journal of Clinical Investigation·2019· 57 citedOpen Access
Sequential somatic mutations upon secondary anti-HER2 treatment resistance in metastatic ERBB2S310F mutated extramammary Paget’s disease
Oncotarget·2019· 12 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Kevin J. Harrington(22), Makoto Tahara(20), Gilberto de Castro(13), Thorsten Fuereder(13), Barbara Burtness(12), Richard Greil(12), Amanda Psyrri(12), Danny Rischin(12), Denis Soulières(11), Brett Hughes(11), Nuttapong Ngamphaiboon(11), Wan Zamaniah Wan Ishak(11), Burak Gümüşçü(11), Lisa Licitra(10), Åse Bratland(10), Ricard Mesı́a(10), Robert L. Ferris(8), George R. Blumenschein(8), Jérôme Fayette(8), J. Guigay(8)